The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer
Open Access
- 2 January 2007
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 117 (1), 218-228
- https://doi.org/10.1172/jci28803
Abstract
The retinoblastoma tumor suppressor (RB) protein is functionally inactivated in the majority of human cancers and is aberrant in one-third of all breast cancers. RB regulates G1/S-phase cell-cycle progression and is a critical mediator of antiproliferative signaling. Here the specific impact of RB deficiency on E2F-regulated gene expression, tumorigenic proliferation, and the response to 2 distinct lines of therapy was investigated in breast cancer cells. RB knockdown resulted in RB/E2F target gene deregulation and accelerated tumorigenic proliferation, thereby demonstrating that even in the context of a complex tumor cell genome, RB status exerts significant control over proliferation. Furthermore, the RB deficiency compromised the short-term cell-cycle inhibition following cisplatin, ionizing radiation, and antiestrogen therapy. In the context of DNA-damaging agents, this bypass resulted in increased sensitivity to these agents in cell culture and xenograft models. In contrast, the bypass of antiestrogen signaling resulted in continued proliferation and xenograft tumor growth in the presence of tamoxifen. These effects of aberrations in RB function were recapitulated by ectopic E2F expression, indicating that control of downstream target genes was an important determinant of the observed responses. Specific analyses of an RB gene expression signature in 60 human patients indicated that deregulation of this pathway was associated with early recurrence following tamoxifen monotherapy. Thus, because the RB pathway is a critical determinant of tumorigenic proliferation and differential therapeutic response, it may represent a critical basis for directing therapy in the treatment of breast cancer.This publication has 59 references indexed in Scilit:
- Apoptosis Inhibition by the Human DEK Oncoprotein Involves Interference with p53 FunctionsMolecular and Cellular Biology, 2006
- Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve PrognosisJNCI Journal of the National Cancer Institute, 2006
- A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer PatientsCancer Research, 2005
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- Direct coupling of the cell cycle and cell death machinery by E2FNature, 2002
- Truncating mutations of RB1CC1 in human breast cancerNature Genetics, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- The Hallmarks of CancerCell, 2000
- Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survivalEuropean Journal of Cancer, 1995
- Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycleEuropean Journal of Cancer and Clinical Oncology, 1983